RXRX Stock — Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc. (RXRX)

Updated October 16, 2026.

RXRX is a Stock. Total return is -88.9% over the past 5.5 years, 185.7 points behind SPY at 96.8%.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses integrated technological platforms spanning biology, chemistry, automation, data science, and engineering to accelerate drug discovery and development. The company's pipeline includes multiple candidates in early clinical trials targeting oncology, rare genetic disorders, and other conditions, with collaboration agreements established alongside major pharmaceutical partners including Roche, Sanofi, and Bayer. As a pre-revenue clinical-stage biotech firm, it does not currently pay distributions and is oriented toward capital appreciation rather than income generation, appealing primarily to growth-focused investors with tolerance for the risks inherent in early-stage pharmaceutical development.

RXRX performance versus SPY

Price and return data through 2026-10-16.

Total return is -88.9% over the past 5.5 years, 185.7 points behind SPY at 96.8%. Over the past year its total return — price change plus distributions reinvested — is -45.5%. Its deepest 1-year drawdown was 57.5%.

RXRX key facts

Asset type

Stock

Asset class

Equity

Inception date

04/16/2021

Distribution frequency

None

Last close

$3.46 (as of 2026-10-16)

Market cap

$1,854,960,619

Average volume

40538634.0

Beta

1.032

Payout ratio

0.0%

EPS

$-1.09

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RXRX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 57.5%.

Who may consider RXRX — and who may not

It is a weaker fit for investors who need monthly cash flow (RXRX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on RXRX

• All tickers starting with R

Tagged: Healthcare.

Frequently asked questions